Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/14/2017 08/15/2017 08/16/2017 08/17/2017 08/18/2017 Date
16.1(c) 16.25(c) 16.3(c) 16.05(c) 15.9 Last
358 186 391 079 313 321 317 883 299 394 Volume
+2.88% +0.93% +0.31% -1.53% -0.93% Change
More quotes
Financials ($)
Sales 2017 170 M
EBIT 2017 -18,4 M
Net income 2017 -19,6 M
Debt 2017 -
Yield 2017 -
Sales 2018 203 M
EBIT 2018 1,77 M
Net income 2018 -5,22 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 4,23x
Capi. / Sales2018 3,55x
Capitalization 720 M
More Financials
Company
Vanda Pharmaceuticals, Inc. engages in the research, development, and commercialization of biopharmaceutical products.It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder.Its product portfolio includes HETLIOZ,... 
More about the company
Surperformance© ratings of Vanda Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on VANDA PHARMACEUTICALS INC.
08/03 VANDA PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
08/02 VANDA PHARMACEUTICALS : reports 2Q loss
08/02 VANDA PHARMACEUTICALS INC. (NASDAQ : VNDA) Files An 8-K Results of Operations an..
08/02 VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fina..
08/02 VANDA PHARMACEUTICALS : Reports Second Quarter 2017 Financial Results
08/02 VANDA PHARMACEUTICALS INC. : Investor Network: Vanda Pharmaceuticals Inc. to Hos..
07/27 VANDA PHARMACEUTICALS : to Announce Second Quarter 2017 Financial Results on Aug..
07/27 VANDA PHARMACEUTICALS : Patent Issued for Intermediate and Process Useful in the..
07/21 VANDA PHARMACEUTICALS : Receives Negative Opinion for Marketing Authorization fr..
07/20 VANDA PHARMACEUTICALS : U.S. Patents Awarded to Inventors in Indiana (July 20)
More news
Sector news : Bio Therapeutic Drugs
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Bio Therapeutic Drugs
Latest Tweets
08/16Vanda Pharmaceuticals Inc. $VNDA Shares Sold by California Public Employees R.. 
08/15Vanda Pharmaceuticals Inc. $VNDA Receives Consensus Recommendation of “Buy” f.. 
08/11Vanda Pharmaceuticals downgraded by BidaskClub to sell.  
08/11UNUSUAL BUYING DETECTED IN BIOTECH $VNDA
1
08/10$VNDA BULL SWEEPERS DETECTED
1
More tweets
Qtime:15
News from SeekingAlpha
08/02 Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q2 2017 Results - ..
08/02 Vanda Pharmaceuticals beats by $0.31, beats on revenue
08/01 Notable earnings after Wednesday?s close
07/26 VANDA PHARMACEUTICALS : An Early Stage Bioscience Consideration
07/21 European regulator rejects Vanda's marketing application for schizophrenia me..
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Technical analysis trends VANDA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 21,5 $
Spread / Average Target 34%
EPS Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Vincent J. Milano Independent Director
Michael F. Cola Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS INC.0.63%720
AMGEN14.77%122 447
CELGENE CORPORATION10.22%99 812
GILEAD SCIENCES1.02%94 471
REGENERON PHARMACEUTICALS27.64%49 721
VERTEX PHARMACEUTICALS101.63%37 450